CALLDORADO
8.9.2021 11:29:08 CEST | Business Wire | Press release
Calldorado has acquired longstanding partner Appvestor in a deal that will give its community of app developers instant access to advanced user acquisition tools.
The two companies make a good fit. Both are dedicated to helping app makers grow but in different ways. Calldorado’s unique technology helps Android developers keep existing user bases active and monetize them. Meanwhile, Appvestor’s AI-powered tools help them find new customers.
Appvestor was established in 2017 to build a technology engine that deploys machine learning and predictive algorithms to establish the best destinations for paid marketing campaigns. Its complete service to developers includes:
- A technology engine that maps campaign progress against revenue, conversion, and retention at a user level.
- Experience in running marketing campaigns that deliver large volumes of new users and the highest return on investment.
- Access to creative resources including studio and production.
- Expertise in ASO (App Store Optimization), which boosts the impact of campaigns and the number of customer conversions.
Calldorado has been working closely with Appvestor since its launch. Mathias Schroeder, co-CEO and co-founder of Calldorado, believes the buy-out is a logical move for both parties. He says: “Our tech does a brilliant job of keeping app users engaged. But it doesn’t find new ones. That’s why we have worked with many user acquisition platforms in the past.
"Appvestor was always the best. It’s the only one with predictive algorithms that can dynamically adjust a marketing campaign to maximize return on investment at all times. Paid user acquisition is a key strategic asset for us, so acquiring Appvestor makes perfect sense. We can’t wait to combine the two companies’ skills into a service that can really help scale our first-party and customer apps.”
The acquisition comes at a time of rapid growth in the app market. Total app downloads across both iOS and Google Play hit 130 billion (1 ). This was a 10% increase on 2019.
Meanwhile, total consumer spend on apps (in-app purchases, subscriptions, and premium apps) reached $143 billion in 2020 – up 20% in a year. App Annie believes the total could hit $270 billion by 2025.
The buoyant app market has fuelled a fast-growing app install ad sector. Developers increasingly rely on paid marketing to drive installs. So much so that analysts expect the total spend to rise from $57.8 billion in 2019 to $118 billion in 2022 (2).
About Calldorado
Calldorado’s unique user activation and monetization technology, the Caller SDK, helps Android app publishers keep their app user bases active, drives incremental traffic, and maximizes app revenue. Calldorado also publishes first-party apps; it launched its own content business with the acquisition of CIAmedia in 2018. A year later it acquired the call enrichment specialist adaffix. Calldorado was established in 2016 with headquarters in Denmark and is privately held.
1. Source: App Annie – State of Mobile 2021 https://www.appannie.com/en/go/state-of-mobile-2021/
2. Source: Appsflyer https://www.appsflyer.com/blog/trends-insights/app-install-ad-spend/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005536/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom